Virtual Meeting
Sobi is committed to providing you with ongoing support

Schedule a virtual discussion with a Gamifant Health Systems Director today.


Gamifant targets a key cytokine In primary HLH1

Gamifant is the only treatment specifically designed to target and neutralize interferon gamma (IFNγ), a key upstream mediator of the proinflammatory cytokine storm associated with primary hemophagocytic lymphohistiocytosis (HLH).1-4

  • Neutralizing IFNγ calms hyperinflammatory symptoms1
  • Gamifant was shown to be effective in patients with refractory, recurrent, or progressive disease or intolerance to conventional therapy1
  • Gamifant is the first and only FDA-approved treatment for primary HLH1,2

Gamifant blocks IFNγ signaLING

Gamifant is a monoclonal antibody that binds to soluble and receptor-bound forms of IFNγ. Binding to IFNγ neutralizes its activity, blocking its intracellular signaling to inhibit macrophage activation and the downstream release of proinflammatory cytokines.1,4-8

Gamifant was shown to neutralize IFNγ

Although the chemokine CXCL9 is not recommended as a diagnostic marker, nor is it needed to begin treatment or for follow-up monitoring, it is a recognized marker for IFNγ activity. In a clinical trial, sustained and consistent reductions in the plasma concentrations of CXCL9 showed that IFNγ was effectively neutralized by Gamifant.1,6

See the data
CXCL9 is an important marker for primary HLH9

CXCL9 is 1 of 3 chemokines in the CXC subfamily predominantly induced by IFNγ. CXCL9 helps regulate immune responses, hematopoietic development, and cell-to-cell communication by acting as a mediator and modulator.10-14

In primary HLH, CXCL9 is produced by IFNγ-activated macrophages. CXCL9 is also a chemoattractant for activated T cells, especially the Th1 cells that produce IFNγ. Thus, higher levels of CXCL9 can indicate IFNγ activity.13